ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 471

When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA

Susan J. Bartlett1, Orit Schieir 2, Marie-France Valois 3, Carol Hitchon 4, Louis Bessette 5, Glen Hazlewood 6, Carter Thorne 7, Janet Pope 8, Gilles Boire 9, Diane Tin 10, Edward Keystone 11, Vivian Bykerk 12 and Canadian Early Arthritis Cohort (CATCH) Investigators 13, 1McGill University, Montreal, QC, Canada, 2University of Toronto, Montreal, Canada, 3McGill University, Montreal, Canada, 4University of Manitoba, Winnipeg, Canada, 5Laval University, Quebec City, QC, Canada, 6University of Calgary, Calgary, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada, 8Western University, London, ON, Canada, 9Sherbrooke University, Sherbrooke, QC, Canada, 10Southlake Regional Health Centre, Newmarket, Canada, 11Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 12Hospital for Special Surgery, New York City, NY, 13Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: , , ,

Session Information

Date: Sunday, November 10, 2019

Session Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Although overwhelming fatigue is common at the onset of RA, some patients continue to experience debilitating high levels of fatigue that impact mood, interfere with work and home life, social participation, and result in poor QoL. Among people with high fatigue at diagnosis, we examined characteristics and identified predictors associated with improved vs. persistent fatigue in the first year of RA.

Methods: Data were from early RA patients (symptoms < 1 year) enrolled in the Canadian Early Arthritis Cohort (CATCH) from 01-2007 to 03-2017. All met ACR1987 or 2010 ACR/EULAR criteria, had active disease, were on DMARDS, and complete fatigue (0-10 NRS) data over ≥ 12 months. Patients were classified at baseline with low (< 4) or high (≥  4) fatigue; patients who reported high fatigue at baseline were categorized at 12 months as having improved (↓ ≥ 2) or persistently (↓ < 2) high fatigue and multivariable logistic regression was used to identify baseline predictors of improvement.

Results: Participants (N=1002) were mostly white (81%) and female (71%) with a mean (SD) age of 54 (15); 32% were obese. At diagnosis, 70% reported high levels of fatigue; as compared to those with low fatigue, high fatigue patients were significantly (p >.05) more likely to have high disease activity and OA/back pain, be obese, and report greater pain, disability, sleep disturbance, depression, and major stressors in the previous year (Table 1). There was a trend for high fatigue patients to be female and seropositive.

At 12 months, 70% of patients with high fatigue reported significant improvements in fatigue. Patients with improved fatigue were significantly less likely to be obese or have fibromyalgia, and had fewer comorbidities, a shorter symptom duration, and lower initial fatigue (Table 2). In adjusted multivariable models, baseline predictors of improved fatigue at 1 year was BMI < 30 (OR 0.6; 95% CI 0.4, 0.9) after controlling for other Table 1 characteristics.

Conclusion: Debilitating fatigue is common around the time of RA diagnosis and is associated with more active disease, worse pain and disability, and OA/back pain, obesity, depression, poor sleep, and major stressors in the previous year. In patients who presented with high fatigue, 70% improved by the end of the first year. Obesity decreased the odds of improved fatigue at 12 months by 40%. In contrast, other RA presenting characteristics were not associated with improvement. Early MTX use and optimizing weight, sleep, and mood may help address persistent fatigue when RA inflammation is well controlled. These results underscore the potential benefits of multidisciplinary interventions in ERA.


Table 1 Who Improves Fatigue

Disclosure: S. Bartlett, Abbie, 2, Abbvie, 2, 5, Bayer, 5, International Society of QOL Research, 6, Janssen, 5, 8, Lilly, 5, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, Pfizer Inc, 8, PROMIS International, 6, UCB, 5, 8; O. Schieir, None; M. Valois, None; C. Hitchon, Pfizer, 2, UCB, 2, UCB Canada, 2; L. Bessette, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Amgen, 2, 5, 8, Amgen, BMS, Janssen, Roche, UCB Pharma, AbbVie Inc, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, and Novartis., 2, 5, 8, BMS, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Bristol-Myers-Squibb, 2, 5, 8, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Eli Lilly and Company, 2, 5, 8, Janssen, 2, 5, 8, Lilly, 2, 5, 8, Merck, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, Roche, 2, 5, 8, Sanofi, 2, 5, 8, UCB, 2, 5, 8, UCB Pharma, 2, 5; G. Hazlewood, None; C. Thorne, Abbvie, 2, 5, Amgen, 2, 5, CaREBiodam, 2, Celgene, 2, 5, Centocor, 5, Janssen, 5, Lilly, 5, Medexus/Medac, 5, 8, Merck, 5, Novartis, 2, 5, Pfizer, 2, 5, Sandoz, 5, Sanofi, 5; J. Pope, AbbVie, 5, Abbvie, 5, Actelion, 5, Actellion, 5, Amgen, 2, 5, AstraZeneca, 2, Astra-Zeneca, 2, Bayer, 2, 5, BMS, 2, 5, Eicos Sciences, 5, Eli Lilly & Company, 5, Eli Lilly and Company, 5, EMERALD, 5, Emerald, 5, Genzyme, 5, Janssen, 5, Lilly, 5, Merck, 2, 5, Novartis, 5, Pfizer, 2, 5, Roche, 2, 5, Sandoz, 5, Sanofi, 5, Seattle Genetics, 2, UCB, 2, 5, 8; G. Boire, Abbvie, 2, Amgen, 2, 5, BMS, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Celgene, 5, Eli Lilly, 2, 5, Lilly, 2, 5, Merck, 2, 8, Novartis, 2, Pfizer, 2, 5, 8; D. Tin, None; E. Keystone, Abbvie, 2, 5, 8, Amgen, 2, 5, 8, AstraZeneca, 5, Astra-Zeneca, 5, Biotest, 5, BMS, 2, 5, 8, Celltrion, 5, Crescendo, 5, Crescendo Bioscience, 5, F. Hoffmann-La Roche Inc, 2, 5, 8, Genentech, 5, Genentech Inc., 5, Genzyme, 5, Gilead, 2, 5, Gilead Sciences, Inc., 5, Janssen, 2, 5, 8, Lilly, 2, 5, 8, Merck, 5, 8, Pfizer, 2, 5, 8, Pfizer Pharmaceuticals, 2, 5, 8, Roche, 2, 5, 8, Sandoz, 5, Sanofi, 2, 5, 8, Sanofi-Aventis, 2, 8, UCB, 5, 8; V. Bykerk, AbbVie, 5, Amgen, 1, 2, 3, 5, 8, Brainstorm Therapeutics, 1, 2, 3, 5, 8, Bristol-Myers Squibb, 5, Genentech, 5, Gilead, 5, NIH, 2, Pfizer, 1, 2, 3, 5, 8, Regeneron, 5, Regeneron Pharmaceuticals, Inc, 5, Sanofi, 5, Sanofi/Genzyme-Regeneron, 5, Sanofi-Genzyme/Regeneron, 1, 2, 3, 5, 8, Scipher, 1, 2, 3, 5, 8, The Cedar Hill Foundation, 9, UCB, 1, 2, 3, 5, 8, UCB Pharma, 5; C. (CATCH) Investigators, Amgen, 2, Pfizer Canada, 2, AbbVie Corporation, 2, Medexus Inc., 2, Eli Lilly Canada, 2, Merck Canada, 2, Sandoz Canada Biopharmaceuticals, 2.

To cite this abstract in AMA style:

Bartlett S, Schieir O, Valois M, Hitchon C, Bessette L, Hazlewood G, Thorne C, Pope J, Boire G, Tin D, Keystone E, Bykerk V, (CATCH) Investigators C. When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/when-will-i-get-past-this-exhaustion-predictors-of-improved-fatigue-in-the-first-year-of-ra/. Accessed July 1, 2022.

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/when-will-i-get-past-this-exhaustion-predictors-of-improved-fatigue-in-the-first-year-of-ra/